Other MAPS Marijuana Related Issues

Additional Resources

  • Visit Marijuana Policy Project, a lobbying organization which has assisted in putting pressure on NIDA on behalf of research
  • Website of Dr. Lester Grinspoon and James. B. Bakalar of Harvard Medical School, authors of Marihuana: The Forbidden Medicine
  • For information about California State-funded medical marijuana research projects, coordinated by the Center for Medicinal Cannabis Research (CMCR), look here.
  • For information about GW Pharmaceutical Company research into the medical uses of marijuana extracts, see their website
History of MAPS Orphan Drug Designation for Smoked Marijuana for AIDS Patients

On May 25, 1999, MAPS successfully secured Orphan Drug Designation for Marijuana in the treatment of AIDS wasting syndrome. Since it is not possible to obtain a patent on marijuana for use as a prescription medicine, an Orphan Drug Designation makes marijuana available for research and development into a prescription medicine. The Orphan Drug Designation program was developed by congress to facilitate the development of rare drugs. In the years since MAPS obtained permission to study this treatment, the advent of protease inhibitors has largely eliminated AIDS wasting syndrome in the US. As a result, we have not pursued this research.

Articles from the MAPS’ Bulletin

SUMMARY: Published in MAPS Bulletin Volume IX Number 3 
MAPS Succeeds in Securing an Orphan Drug Designation for Marijuana (1999)

Past MAPS Marijuana Studies
Follow these links for information about MAPS’ sponsored Medical Marijuana studies

  1. No trackbacks yet.

You must be logged in to post a comment.
%d bloggers like this: